一分钟看懂
这是一项关于子宫内膜癌的III 期研究，登记的药物或干预包括BNT323/DB-1303；Doxorubicin；Paclitaxel；Docetaxel，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BNT323/DB-1303；Doxorubicin；Paclitaxel；Docetaxel · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Hospital · 合肥
- Beijing Cancer Hospital · 北京
- The Second Affiliated Hospital of Chongqing Medical University · 重庆
- Fujian Provincial Cancer Hospital · 福州
- First Affiliated Hospital of Xiamen University · 厦门
- Gansu Provincial Maternity and Child-care Hospital · 兰州
- The First Affiliated Hospital of Sun Yat-sen University · 广州
- Cancer Hospital of Shantou University Medical College · 汕头
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Harbin Medical University Cancer Hospital · 哈尔滨
- The Second Affiliated Hospital of Zhengzhou University · 郑州
- Hubei Cancer Hospital · 武汉
- Xiangyang Central Hospital · 襄阳
- The Affiliated Hospital of Nanjing University Medical School · 南京
- Jiangxi Maternal and Child Health Hospital · 南昌
- The First Hospital of Jilin University · 长春
- The First Affiliated Hospital of Xian Jiaotong University · 西安
- Cancer Hospital of Shandong First Medical University · 济南
- Affiliated Hospital of Jining Medical University · 济宁
- Linyi Cancer Hospital · 临沂
- Yantai Yuhuangding Hospital · 烟台
- Obstetrics & Gynecology Hospital of Fudan University · 上海
- Fudan University Shanghai Cancer Center · 上海
- Sichuan Provincial People's Hospital · 成都
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Zhejiang Cancer Hospital · 杭州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
公开的入选条件
- * Are female adults (defined as ≥18 years of age or acceptable age according to local regulations at the time of voluntarily giving informed consent).
- * Have histologically confirmed endometrial cancer that:
- Is recurrent,
- Has a HER2 IHC score of 1+, 2+ (Cohort 1), or 3+ (Cohort 2) as determined by central laboratory testing for HER2 expression, and
- Is not defined as a true sarcoma (i.e., leiomyosarcoma or endometrial stromal sarcoma). Note: Uterine carcinosarcoma is allowed.
- * Have measurable disease defined by RECIST v1.1.
- * Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
- * Have recurrent endometrial cancer and meet any of the following:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06340568；登记信息更新于 2026-09-17。